• Target：
• p57

• Fields：
• >>Cell cycle

• Gene Name：
• CDKN1C

• Protein Name：
• Cyclin-dependent kinase inhibitor 1C

• Human Gene Id：
• 1028

• Human Swiss Prot No：
• P49918

• Mouse Gene Id：
• 12577

• Mouse Swiss Prot No：
• P49919

• Immunogen：
• Synthesized peptide derived from human protein. AA range:200-316

• Specificity：
• The antibody can specifically recognize human p57kip2 protein.

• Formulation：
• PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

• Source：
• Mouse, Monoclonal/IgG2b, kappa

• Dilution：
• IHC 1:200-1000. WB 1:500-2000. IF 1:100-500. ELISA 1:1000-5000

• Purification：
• Protein G

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• Beckwith Wiedemann syndrome；BWCR；BWS；CDKI；CDKN 1C；CDKN1C；CDN1C_HUMAN；Cyclin dependent kinase inhibitor 1C；Cyclin dependent kinase inhibitor p57；Cyclin-dependent kinase inhibitor 1C；Cyclin-dependent kinase inhibitor p57；KIP 2；KIP2；p57；p57 Kip 2；p57KIP2；WBS

• Molecular Weight(Da)：
• 50kD

• Observed Band(KD)：
• 57kD

• Background：
• P57kip2 is a cell cycle inhibitor and tumor suppressor. The gene is mainly located on the mother's chromosome 11. By blocking the G1 / S phase transition in the cell cycle, we can realize the negative regulation of the cell cycle, and then prevent cell proliferation and tumor formation. In complete hydatidiform mole, there is a lack of maternal gene and p57 negative expression, while in partial hydatidiform mole, there are genes of both parents and p57 positive expression, which can be used for the study of early hydatidiform mole pregnancy.

• Function：
• disease:Defects in CDKN1C are a cause of Beckwith-Wiedemann syndrome (BWS) [MIM:130650]. BWS is a genetically heterogeneous disorder characterized by anterior abdominal wall defects including exomphalos (omphalocele), pre- and postnatal overgrowth, and macroglossia. Additional less frequent complications include specific developmental defects and a predisposition to embryonal tumors.,disease:Defects in CDKN1C are involved in tumor formation.,function:Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life.,similarity:Belongs to the CDI family.,tissue specificity:Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. High levels ar

• Subcellular Location：
• Nuclear

• Expression：
• Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. Expressed in the eye. High levels are seen in the placenta while low levels are seen in the liver.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs